Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | CA3 | P07451 | 2/20 | 0.37 |
| ▸ | CA5A | P35218 | 2/20 | 0.37 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL714350 | 0.96 | MEN1 (0.43) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL27052880 | 0.91 | MEN1 (0.38) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL12500466 | 0.90 | MEN1 (0.34) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL14538806 | 0.85 | EPHX1 (0.45) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL18349839 | 0.83 | EPHX1 (0.36) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL14286753 | 0.83 | — | — | |
| SCHEMBL14538977 | 0.82 | EPHX1 (0.47) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15617410 | 0.82 | — | — | |
| SCHEMBL1687471 | 0.82 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL14538819 | 0.81 | EPHX1 (0.49) | ALDH1A1POLBSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100112619-A1 | LIGAND-CONTAINING MICELLES AND USES THEREOF | GRAHAM RONALD J | 2010-05-06 | — | — | US | disclosed |
| US-20090047699-A1 | FLUOROGENIC ENZYME ACTIVITY ASSAY METHODS AND COMPOSITIONS USING FRAGMENTABLE LINKERS | APPLIED BIOSYSTEMS INC. (US) | 2009-02-19 | — | — | US | disclosed |
| US-20060063147-A1 | Omega-amino-PEG-phosphoramidites and conjugates thereof | U CHICAGO ARGONNE LLC | 2006-03-23 | — | — | US | disclosed |
| US-20040115685-A1 | Immobilisation of ligands | PHARMA GEN SA (ES) | 2004-06-17 | — | — | US | disclosed |
| EP-1366193-A2 | IMMOBILISATION OF LIGANDS USING SACCHARIDES | Pharma Gen S.A. (ES) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072887-A2 | IMMOBILISATION OF LIGANDS USING SACCHARIDES | PHARMA GEN S.A. (ES) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047699-A1 | FLUOROGENIC ENZYME ACTIVITY ASSAY METHODS AND COMPOSITIONS USING FRAGMENTABLE LINKERS | BCHE, SI, ENGASE | ALDH1A1 1711/4885POLB 474/4885SMN1; SMN2 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.